Proficio Capital Partners LLC Raises Holdings in Amgen Inc. $AMGN

Proficio Capital Partners LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 54.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,520 shares of the medical research company’s stock after purchasing an additional 2,286 shares during the period. Proficio Capital Partners LLC’s holdings in Amgen were worth $2,361,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Dogwood Wealth Management LLC increased its position in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Tower View Wealth Management LLC boosted its stake in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares during the last quarter. Manning & Napier Advisors LLC boosted its stake in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Evergreen Advisors LLC purchased a new stake in shares of Amgen during the first quarter worth about $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.

Amgen Stock Down 0.6%

Shares of NASDAQ:AMGN opened at $429.88 on Tuesday. The stock has a 50-day simple moving average of $390.35 and a 200-day simple moving average of $365.09. The stock has a market capitalization of $232.41 billion, a P/E ratio of 26.72, a PEG ratio of 3.12 and a beta of 0.41. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $447.03. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the prior year, the firm earned $6.02 EPS. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts forecast that Amgen Inc. will post 22.97 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio (DPR) is 62.65%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AMGN. Robert W. Baird upped their price objective on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Guggenheim lifted their target price on shares of Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. Mizuho increased their price target on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. Daiwa Securities Group decreased their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Finally, Bank of America lifted their price objective on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $380.43.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha demonstrated a meaningful mortality benefit. Amgen reported that Repatha reduced the risk of death by 20% in more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. The findings came from a prespecified analysis of the Phase 3 VESALIUS-CV trial presented at the 2026 European Society of Cardiology Congress. The result could support broader use of Repatha beyond cholesterol reduction and strengthen one of Amgen’s key revenue drivers. Amgen Repatha clinical results
• Positive Sentiment: Analyst sentiment and performance comparisons remain supportive. Commentary says AMGN has outperformed the broader market over the past year, with analysts moderately bullish on its future prospects. Erste Group Bank also issued a positive forecast for Amgen’s earnings, adding to the favorable outlook. Amgen stock performance comparison
• Neutral Sentiment: Industry growth could provide a secondary opportunity. A new report identifies Amgen among companies participating in the expanding palmoplantar pustulosis market, driven by increased diagnosis and demand for biologic treatments. However, the report does not identify a specific Amgen product or provide a material revenue forecast, so the immediate stock impact is likely limited. Palmoplantar pustulosis market report

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.